Enrollment begins in phase III study of futibatinib in CCA harboring FGFR2 gene rearrangements April 8, 2021
FDA clears IND for phase II study of MIT-001 as therapy of CCRT-induced oral mucositis in HNSCC April 8, 2021
Bridge Biotherapeutics begins phase I/II trial of BBT-176 in EGFR-mutant NSCLC with C797S April 7, 2021
RSS